InTrack Investment Management Inc Buys 3,209 Shares of Danaher Co. (NYSE:DHR)

InTrack Investment Management Inc increased its position in shares of Danaher Co. (NYSE:DHR) by 47.5% during the 4th quarter, Holdings Channel reports. The fund owned 9,969 shares of the conglomerate’s stock after buying an additional 3,209 shares during the quarter. Danaher accounts for about 1.6% of InTrack Investment Management Inc’s investment portfolio, making the stock its 14th biggest holding. InTrack Investment Management Inc’s holdings in Danaher were worth $2,369,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares in the last quarter. Montrusco Bolton Investments Inc. raised its position in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in Danaher by 82.4% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock valued at $181,651,000 after acquiring an additional 295,187 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 1.4 %

Shares of DHR stock opened at $238.41 on Friday. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The stock’s fifty day moving average price is $234.99 and its two-hundred day moving average price is $253.37. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market cap of $172.20 billion, a PE ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.02 earnings per share. Equities analysts predict that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DHR shares. Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target for the company. Barclays lowered their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Finally, UBS Group reduced their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.